What is a stock summary page? Click here for an overview.
Business Description
Orexo AB
ISIN : US68616W1027
Share Class Description:
ORXOY: ADRCompare
Compare
Traded in other countries / regions
ORX.Sweden0H19.UKORXOY.USAC5G.Germany IPO Date
2013-08-28Description
Orexo AB has operations in Sweden and the United States. Operations are monitored and presented in the segments USA Pharma, Digital Therapeutics (DTx), and HQ & Pipeline. The majority is from the USA Pharma segment. Geographically, the majority is derived from the United States. USA Pharma includes the commercialization of fully owned pharmaceuticals in the United States market. Digital Therapeutics include the commercialization of Orexo's groundbreaking evidence-based digital therapeutics, mainly in the United States market, which is in an early development stage. HQ &Pipeline includes the Development of pharmaceuticals performed at Orexo's headquarters in Uppsala, Sweden.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.26 | |||||
| Equity-to-Asset | -0.21 | |||||
| Debt-to-Equity | -3.77 | |||||
| Debt-to-EBITDA | 8.96 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 1.09 | |||||
| Beneish M-Score | -4.01 | |||||
| WACC vs ROIC | ||||||
Growth Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 1.3 | |||||
| 3-Year EPS without NRI Growth Rate | 3.3 | |||||
| 3-Year FCF Growth Rate | 49.2 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 10.11 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 1.95 | |||||
| 9-Day RSI | 11.09 | |||||
| 14-Day RSI | 22.94 | |||||
| 3-1 Month Momentum % | -21.75 | |||||
| 6-1 Month Momentum % | -2.32 | |||||
| 12-1 Month Momentum % | 7.66 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.93 | |||||
| Quick Ratio | 1.67 | |||||
| Cash Ratio | 0.53 | |||||
| Days Inventory | 301.83 | |||||
| Days Sales Outstanding | 141.29 | |||||
| Days Payable | 197.71 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -0.2 | |||||
| Shareholder Yield % | -3.76 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 87.8 | |||||
| Operating Margin % | -23.74 | |||||
| Net Margin % | -34.38 | |||||
| FCF Margin % | -6.47 | |||||
| ROA % | -27.56 | |||||
| ROIC % | -22.74 | |||||
| 3-Year ROIIC % | -25.27 | |||||
| ROC (Joel Greenblatt) % | -77.22 | |||||
| ROCE % | -35.26 | |||||
| Years of Profitability over Past 10-Year | 4 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 0.84 | |||||
| EV-to-EBIT | -6.25 | |||||
| EV-to-Forward-EBIT | 61.89 | |||||
| EV-to-EBITDA | 16.03 | |||||
| EV-to-Forward-EBITDA | 9.74 | |||||
| EV-to-Revenue | 1.44 | |||||
| EV-to-Forward-Revenue | 1.32 | |||||
| EV-to-FCF | -22.81 | |||||
| Price-to-GF-Value | 0.83 | |||||
| Price-to-Median-PS-Value | 0.4 | |||||
| Earnings Yield (Greenblatt) % | -16 | |||||
| FCF Yield % | -7.49 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:ORXOY
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return %
Total Annual Return %
Orexo AB Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 56.002 | ||
| EPS (TTM) ($) | -0.549 | ||
| Beta | 0.96 | ||
| 3-Year Sharpe Ratio | 0.03 | ||
| 3-Year Sortino Ratio | 0.06 | ||
| Volatility % | 84.88 | ||
| 14-Day RSI | 22.94 | ||
| 14-Day ATR ($) | 0.004661 | ||
| 20-Day SMA ($) | 1.475 | ||
| 12-1 Month Momentum % | 7.66 | ||
| 52-Week Range ($) | 0.889 - 2.35 | ||
| Shares Outstanding (Mil) | 34.51 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Orexo AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Orexo AB Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Orexo AB Frequently Asked Questions
What is Orexo AB(ORXOY)'s stock price today?
The current price of ORXOY is $1.48. The 52 week high of ORXOY is $2.35 and 52 week low is $0.89.
When is next earnings date of Orexo AB(ORXOY)?
The next earnings date of Orexo AB(ORXOY) is 2025-05-06.
Does Orexo AB(ORXOY) pay dividends? If so, how much?
Orexo AB(ORXOY) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers